Reveals a Non-Surgical, Cataract Removal Option..
individuals develop serious complications as a result of cataract surgery annually
in the US alone. Thus,
risk and cost factors
drive the investigation of pharmaceutical approaches to the maintenance of lens
transparency. Opacification of the posterior lens capsule occurs in 30-50% of
patients within 2 years of cataract removal and require secondary laser treatment;
further 0.8% experience retinal detachments, approximately 1% are re-hospitalized
corneal problems, and about 0.1% develop endophthalmitis.
The significant complication
rate of cataract surgery, should be sufficient reason to increase cataract research.
Additionally the artificial lens just does not have the same overall optical
qualities of a natural lens.
Even if the development
of cataract can be delayed by 10-years, the overall benefits would be highly
significant..:" Dr. Robert Mason PhD
"Guide to Anti Aging Drugs"
clinical trials patients instilled 2 drops of a
proprietary form of
N-acetyl-carnosine eye drop into each eye 3 to 4 times a day, for a period of
6 months. The results
showed a pronounced effect on cataracts; the effective
rate was 100%, setting an unprecedented benchmark for the treatment and
reversal of cataracts and other eye disorders.." Clinical
last 10 years this, non-invasive, anti-oxidant, eye drop, patented by "Innovative
Vision Products" has generated thousands of reports of safe and effective
Cataract Reversal. Can-C™
Vision Products (IVP)
a US based corporation founded by Dr. Mark Babizhayev, operating in Russia in
co-operation with the "Helmholtz Research Institute of Eye Disease"
Product: N-acetylcarnosine (Can-C™), is manufactured in a cGMP facility
by a UK based licensed manufacturer and we see the demand for this product snowballing
as consumers around the globe become aware of a viable non-surgical option
to cataract surgery."
addition to the very impressive statistical and clinical success rates for patients
within 3-12 months of treatment, it is also interesting to note that
NAC eye-drops are patented for use in open-angle glaucoma, but as yet, the research
for that disorder remains unpublished. [Ed.- We are keen to report on NAC's
benefit for glaucoma as soon as it becomes available, especially as this is
an eye-disorder that is extremely difficult to treat.]
Mark Babizhayev MA, PhD
statistics in the human trials show that Can-C™
Eye Drops applied for 6-months, (twice daily into the eye), in patients
suffering from senile cataract, had the following results:
had an improvement in visual acuity.
had an improvement of glare sensitivity.
had an improvement of the transmissivity of the lens.
I used Can-C™ eye drops for 4-months with amazing results. My
vision in my left eye improved from 20/40 to 20/25 and upon renewal
of my driving license, the eye glass restriction was eliminated!"
Richard Lippman, Hawaii
Dr. Babizhayev, I want to "thank you for the "great" and
"unbelieveable" and,,,,,,,"marvelvelous" eye drops that
you have developed. I use vitamin supplemets for my eyes but without your N-acetylcarnosine
"eye drops", I know that I would be totally "blind" today
from cataracts. I want you to know that I will continue to use these eye drops
indefinitely for maintaining the improved health of my eyes. Thank you! Lawrence
H. - Tucson AZ
ingredient in Can-c™ is a proprietary form of N-acetylcarnosine. A highly
specific intraocular released form of carnosine, patented by Innovative Vision
Products, which acts as both a stabilizer and carrier for the di-peptide L-carnosine,
safely delivering it into the aqueous humour of the eye, (the fluid area surrounding
the lens). It is here, that this bio-identical antioxidant becomes most active
in its anti-cataract activity.
about other eye conditions...?
the information is not yet published, this unique "IVP" N-acetylcarnosine
(Can-C™) formula with its synergistic lubricants, and bioavailable antioxidant
properties, is showing impressive beneficial results for the following eye-disorders.
Intraocular pressure associated with Glaucoma.
• Contact lens disorders.
• Corneal disorders.
• Chronic eyestrain.
• Computer vision syndrome.
• Ocular inflammation.
• Blurred vision.
• Dry eye syndrome.
• Retinal disease
• Vitreous opacities and lesions.
Note: Not only do
the lubricants in the Can-C N-acetylcarnosine eye-drop help to make wearing
contact lenses more comfortable, but n-acetylcarnosine is also believed to reduce
the build up of lactic acid in the eye, thus enabling the lens to be left safely
in the eye for longer.
Manufactured to cGMP pharmaceutical
has a wealth of anti-oxidant properties which can improve the overall function
of the aging eye. Can-C™
- Two (5ml) vials per box
4 drops daily to each affected eye.
month supply) for both eyes = 2 boxes
(2 month supply) for both eyes = 4 boxes
(4 month supply) for both eyes = 8 boxes
(6 month supply) for both eyes = 12 boxes
Information - click
Carnosine eye-drops were
used in a clinical trial to treat 96 patients aged 60 and above. All the patients
had senile cataract in various degrees of maturity. The duration of the disease
in these patients ranged between 2 and 21 years. Firstly, the researchers stopped
the patient's use of all other anti-cataract drugs. Then the patients instilled
1 or 2 drops into each eye 3 or 4 times a day, for a period of 3 to 6 months.
The level of eyesight improvement and the change of lens transparency was considered
as an evaluation index. The results showed that there was a pronounced effect
on primary senile cataract, the effective rate was 100%
(i.e. all patients experienced an improvement. For the more mature senile
cataract (i.e. those who had had the cataract the longest time, in some cases
more than 20-years) the effective rate was still an extremely impressive 80%.
These are remarkable results considering that the best that could normally be
expected would be a slight improvement, a halt to the progression and under
normal (i.e. non-treated) circumstances a continual worsening of the disease.
Importantly, it was also noted that there were no side effects noted in any
of the cases.Clinical
designed to document and quantify the changes in lens clarity over a 6 to 24
month period for 49 volunteers. Their average age was 65 and all suffered from
senile cataract of a minimal to advanced opacification.
The patients received either a 1% solution of NAC eye-drops or a placebo, as
2-drops twice a day into each eye. The patients were then evaluated at 2 and
6-month periods. The tests consisted of ophthalmoscopy (glare test), stereocinematagraphic
(slit-image) and retro-illumination (photography). A computerized digital analysis
then displayed the light scattering and absorbing effects of the centers of
At 6-months, 88.9% of all eyes treated with NAC had an improvement of glare
sensitivity (lowest individual score was a 27% improvement, right the way up
to a 100% improvement. 41.5% of all eyes
treated with NAC had a significant improvement of the transmissivity of the
lens, but perhaps most importantly 90% of the eyes treated
with NAC showed an improvement in visual acuity. Meanwhile, in
the placebo group there was little change in eye quality at 6-months and a gradual
deterioration at 12 to 24 months. Importantly,
this study also showed that at 24-months the NAC treated group, (who already
had significant improvement to the quality of their eyesight), sustained
these results with continued use of the NAC eye-drops. Once
again, no significant side effects were noted in any cases
throughout the 2-year period.
interesting study evaluated
patients between the ages of 48 and 60, who had various degrees of eyesight
impairment, but who did NOT have the symptoms of cataract. After a course of
treatment ranging from 2 to 6 months the conclusion was, that the eye-drops
alleviated eye-tiredness and continued to improve eyesight (i.e. there was more
clear vision). The subjects reported that the treatment "brightened"
and "relaxed" their eyes. This is an important indicator that the
eye-drops have a value both for preventative purposes, as well as medical applications.
this time clear evidence has emerged that NAC eye-drops are a safe, effective
treatment and potential preventative against cataract however Dr.
Mark Babizhayev also makes it quite clear that "ordinary" L-Carnosine
will not be of much use in the treatment of senile-cataract. This is because
there are many synthesized "carnosines" and their biological and medicinal
activity strongly varies and depends on the mode of their obtention. For
example, if carnosine is extracted from meat muscle substances, the biological
and anti-oxidant activity is very low. This is presumably due to the contamination
of the "pure" carnosine substance by heavy metal salts and proteins
and other related impurities. It is very difficult to purify carnosine chromatographically,
as the compound chelates divalent metal ions very heavily and the biological
and anti-oxidant activities can not be regenerated during the purification procedures.
Dr. Babizhayev Interview
N-acetylcarnosine (Can-C™) actually reverses cataracts - Click
NAC eye-drops appear to act as a universal anti-oxidant, both in the lipid phase
of the cellular lens membranes, and in the aqueous environment. NAC eye-drops
reduce and protect the crystalline lens from oxidative stress-induced, cross-linking
damage. There were many forms of carnosine, which were abandoned, in the Russian
studies because of their lack of anti-cataract and anti-oxidant ability in the
human eye, however, Innovative Vision Products (IVP), in conjunction
with their Japanese partner and manufacturer, have developed a synthesized pure
NAC which has biological activity and has been well controlled and proven in
human lens studies. This is the formula that has been used in the clinical trials
under th etrademark name Can-C™.
IVP holds the proprietary knowledge to the correct and efficient production
of a specific purity of NAC. If the label doesn't state it is Approvedby
Innovative Vision Products (IVP), then the source of the raw material is NOT
the one that the clinical trials were conducted with. "Unknown" sources
of carnosine eye-drops should be avoided, as the material could be ineffective,
and possibly even dangerous to the human eye.
is a widespread age-related affliction and NAC eye-drops appear to be a highly
efficacious and safe treatment for cataract. As such, I suspect that this supplement
is going to become one of the most important new discoveries, and will have
a major impact on the way that cataract is controlled." -
our study the clinical effects of a topical solution of N-acetylcarnosine eye
on lens opacities were examined in patients with cataracts and in canines with
age-related cataracts. These
data showed that N-acetylcarnosine (Can-C™) is effective in the management
of age-related cataract reversal and prevention both in human and in canine
15139774 [PubMed - indexed for MEDLINE]
peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage
age-related cataracts in human and in canine eyes. PMID:
15139774 [PubMed - indexed for MEDLINE] Innovative
Vision Products Inc., County of New Castle, Delaware, USA.
1. Boldyrev AA, Dupin AM,
Bunin Aya, Babizhayev MA, Severin SE "The antioxidative properties of carnosine,
a natural histidine containing di-peptide." Biochem. Inrern., 1987, 15/6,
2. Babizhayev MA et al "N-Acetylcarnosine, a natural histidine-containing
di-peptide, as a potent ophthalmic drug in treatment of human cataracts."
Peptides (USA) 2001, 22(6): 979-994.
3. Babizhayev MA, Yermakova VN, Deyev Al, Seguin M-C "Imidazole-containing
peptiomimetic NACA as a potent drug for the medicinal treatment of age-related
cataract in humans." J. Anti-Aging Medicine 2000, 2, 43-62.
4. Babizhayev MA, Yermakova VN, Semiletov yu A, Deyev Al "The natural histidine-containing
di-peptide N-acetylcarnosine as an antioxidant for ophthalmic use." Biochemistry
(Moscow), 2000, 65, 588-598.
5. Babizhayev MA, Yermakova VN, Sakina NL, Evstigneeva RP, Rozhkova EA, Zheltukhina
GA "N-Acetycarnosine is a prodrug of L-carnosine in ophthalmic application
as antioxidant." Clin. Chim. Acta., 1996, 254, 1-21.
6. Babizhayev MA, Bozzo Costa E "Composizioni farmaceutiche contenenti
N-acetilcarnosina per il trattamento della cataratta." A61K gruppo 37/00
cap 20122 MI 15.10.1993. Italian patent.
7. Babizhayev MA, Bozzo Costa E "Pharmaceutical compositions containing
N-Acetylcarnosine for the treatment of cataract." European Patent PCT/EP
94/03340 10.10.1994 Ref. SCB 238 PCT.
8. Babizhayev MA, Seguin M-C, Gueyene J, Evstigneeva RP, Ageyeva EA, Zheltukhina
GA "L-carnosine and carcinine act as natural antioxidants with hydroxyl-radical-scavenging
and lipid peroxidase activities." Biochem J. 304, 509-516.
9. Babizhayev MA, "Antioxidant activity of L-carnosine, a natural histidine-containing
di-peptide in crystalline lens." Biochem. Biophys. Acta., 1989, 1004, 363-371.
10. Babizhayev MA, Deyev Al "Lens opacity induced by lipid peroxidation
products as a model of cataract associated with retinal disease." Biochim.
Biophys. Acta., 1989, 1004, 124-133.
11. Babizhayev MA, Deyev Al "Free radical oxidation of lipid and thiol
groups in genesis of cataract." Biophysics (biofizika), 1986, 31, 119-125,
Pergamon Journals Ltd.
12. Kantha S, Wada S, Tanaka H, Takeushi M, Watabe S, Ochi H (1966), Biochem.
Biophys. Res. Commun. 223, 278-292.
13. Babizhayev MA, Deyev Al, Linberg LF "Lipid peroxidation as a possible
cause of cataract." Mech. Ageing Dev. 1988, 44, 69-89.
14. Boldyrev AA, "Problems and perspectives in studying the biological
role of carnosine" International Center for Biotechnology, Department of
Biochemistry, Lomonosov, Moscow State University.
15. Hipkiss A, (1998) Int. J. Biochem. Mol. Biol., 30, 863-868.
16. Boldyrev AA, Dupin A, Bunin A, Babizhayev MA, Severin SE (1987), Biochem.
Int., 15, 1107-1113.
17. Wang AM, Ma C, Xie H, F Shen "Medical application of carnosine "
Department of Biochemistry and Neurobiology, Harbin Medical University, China.
18. World Health Organisation, Ageing and Health, Website: http://www.who.int/ageing/scope.htm
DISCLAIMER: ALL INFORMATION IS EDUCATIONAL AND DOES NOT, AND SHOULD NOT, REPLACE
THE ADVICE OF YOUR PHYSICIAN.
Last Updated: Tuesday, July 20, 2004
Dr. Babizhayev Interview